Skip to main content

Table 2 Treatment emergent adverse effects in the study participants

From: The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson’s disease: a randomized, double-blind, double-dummy, parallel-group study

Characteristic Pramipexole ER Pramipexole IR Total
n=234 n=239 n=473
Patients with any AE 161(68.8) 176(73.6) 337(71.2)
  Severe AEs 5(2.1) 9(3.8) 14(3.0)
  Drug-related AEs 117(50) 126(52.7) 243(51.4)
  AEs leading to discontinuation 11(4.7) 12(5.0) 23(4.9)
  Serious AEs 6(2.6) 13(5.4) 19(4.0)
Nervous system disorders 96(41.0) 88(36.8) 184(38.9)
  Somnolence 51(21.8) 35(14.6) 86(18.2)
  Dizziness 30(12.8) 31(13.0) 61(12.9)
  Dyskinesia 12(5.1) 18(7.5) 30(6.3)
  Tremor 4(1.7) 6(2.5) 10(2.1)
  PD 3(1.3) 9(3.8) 12(2.5)
Gastrointestinal disorders 60(25.6) 58(24.3) 108(22.8)
  Nausea 20(8.5) 17(7.1) 37(7.8)
  Constipation 17(7.3) 20(8.4) 37(7.8)
  Abdominal discomfort 3(1.3) 7(2.9) 10(2.1)
  Upper abdominal pain 6(2.6) 6(2.5) 12(2.5)
  Vomiting 5(2.1) 5(2.1) 10(2.1)
Eye disorders 11(4.7) 8(3.3) 19(4.0)
Vascular disorders 8(3.4) 11(4.6) 19(4.0)
  Orthostatic hypotension 5(2.1) 4(1.7) 9(1.9)
  Hypotension 1(0.4) 5(2.1) 6(1.3)